TG Therapeutics | TGTX - Cost Of Sales


TG Therapeutics reported $41.19M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Alaunos Therapeutics USD 0 18K Sep/2024
Amgen USD 1.87B 271M Jun/2026
Ardelyx USD 4.81M 6.04M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Biogen USD 945.1M 147.6M Jun/2026
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Curis USD 314K 9.96M Dec/2025
Gilead Sciences USD 1000M 445M Jun/2026
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Novartis USD 3.71B 251M Jun/2026
Novavax USD 22.1M 608K Dec/2025
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
TG Therapeutics USD 41.19M 7.68M Jun/2026
Verastem USD 3.05M 159K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026